b'REIMAGINECYTOMETRYAND SEE HOW QUICKLY YOUR CLINICAL RESEARCH MOVES AHEAD.Developing effective therapies rapidly,the impact of drugs on signalingSIMPLIFY THE DESIGN efficiently and with minimal risk is criticalpathways, tumor microenvironmentAND EXECUTION OF DEEP to the advancement of precision medicine.biology in response to immunotherapyCELL-PROFILING STUDIES.However, the complex and unique natureand the efficacy of vaccine candidates, of every patients immune system posesto name only a few. STANDARDIZE SAMPLE challenges to achieving this goal. It is noThe proven reproducibility of massANALYSIS WITH REPRODUCIBLE longer sufficient to rely on the cell profilingcytometry, run-to-run and site-to-site,WORKFLOWS AND AUTOMATION.approaches of the past. combined with the robust nature of its ACCELERATE NOVEL By quickly and easily providing themetal-tagged antibodies and uniqueTHERAPEUTIC DEVELOPMENT highest-resolution proteomic cellbarcoding technology has led toTO IMPROVE HUMAN profiles of any cytometry platform, massits adoption in scores of clinical and cytometry provides the most reliabletranslational research studies as wellHEALTH OUTCOMES.and comprehensive way to captureas by multiple research consortia. immune complexity.Now, the technology has advanced even Mass cytometry generates an unrivaled,further with automated sample acquisition high-parameter snapshot of phenotypeand internal systems monitoring that enable and function for every cell. This ability hashands-free, flexible operation.advanced our understanding of diseaseThe next evolution of mass and therapeutic benefit with novel insightscytometry is hereCyTOF XT.into the function of checkpoint inhibitors, Achieve the unimaginable.2'